The PAK1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, providing a loss-of-function model to study the serine/threonine kinase PAK1. This product consists of a heterogeneous pool of edited cells with targeted disruption of the PAK1 gene, enabling robust functional interrogation of PAK1-dependent pathways without the clonal biases associated with single-cell isolates.
The Raji cell line is a well-characterized lymphoblastoid model established from a Burkitt’s lymphoma patient. These cells are Epstein-Barr virus (EBV)-positive and retain many features of transformed B lymphocytes, making them a staple in immunological and cancer research. Raji cells are widely employed to investigate B cell neoplasia, immune signaling mechanisms, and mechanisms of lymphomagenesis, offering a physiologically relevant background for studying oncogenic kinase function.
PAK1 functions as a key downstream effector of the Rho GTPases RAC1 and CDC42, integrating signals from growth factor receptors (e.g., EGFR, PDGFR), integrins, and PI3K to regulate cytoskeletal dynamics, cell motility, proliferation, and survival. The kinase directly phosphorylates substrates such as LIMK1 and MLCK to control actin reorganization, and activates the RAF1/MEK/ERK cascade to promote transcription. Additionally, PAK1 phosphorylates BAD to suppress apoptosis and stimulates NF??B to drive survival gene expression. PAK1 also interacts with adaptor proteins NCK and PIX, and forms complexes with ??-catenin and Akt, highlighting its role as a signaling hub.
In the context of B lymphocytes, PAK1 is implicated in both normal immune function and malignant transformation. Aberrant PAK1 activity has been associated with dysregulated proliferation, enhanced survival, and altered cytoskeletal dynamics in B-cell lymphomas. The PAK1 Knockout Raji Polyclonal Cells thus enable dissection of PAK1’s specific contributions to lymphomagenesis, immune synapse formation, and the pathobiology of Burkitt’s lymphoma, providing a clean genetic background to study these processes without compensation from intact PAK1 alleles.
Researchers can utilize this knockout model in diverse applications including investigation of PAK1-mediated signaling in B-cell lymphoma, validation of PAK1 as a therapeutic target, and dissection of its roles in cell migration and proliferation. Compatible assays include Western blotting for PAK1 and downstream phospho-substrates, flow cytometry for apoptosis and proliferation, transwell migration/invasion assays, phospho-signaling multiplex analysis, drug sensitivity screening, and RT-qPCR for pathway gene expression. For further information or technical support, please contact Ascent Research.
